Chemomab Therapeutics (CMMB) Stock: Buy, Sell, or Hold?
CMMB - Chemomab Therapeutics Ltd. American Depositary Share
$1.05
0.05 (5.00%)
▲
5d:
-11.02%
30d:
-35.98%
90d:
-28.08%
WAIT
LOW Confidence
Analysis Updated: Oct 27, 2026 12:00 AM ET
Earnings: Oct 29, 2026
TODAY
Get Alerted When CMMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CMMB is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CMMB is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CMMB is currently trading at $1.05, which is considered slightly low relative to its 30-day fair value range of $1.05 to $1.90.
Technical Outlook: Technically, CMMB is showing sideways momentum. Immediate support is located at $0.92, while resistance sits at $1.35. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.00 (+376.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CMMB is showing sideways momentum. Immediate support is located at $0.92, while resistance sits at $1.35. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.00 (+376.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.05 -
$1.90
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 376.2% below Wall St target ($5.00)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.05 -
$1.90
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.92
Resistance Level
$1.36
Current Trend
Sideways
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-35.00
Wall Street Target
$5.00
(+376.2%)
Share & Embed Analysis
Last updated: October 28, 2026 7:45 AM ET
Data refreshes hourly during market hours. Next update: 8:45 AM
Data refreshes hourly during market hours. Next update: 8:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CMMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$196 | 68 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
23 analysts |
$109 | 62 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$685 | 59 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 71 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 68 BUY |
